The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10509 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drug resistance

NOT Open Access | Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in Ghana Using Molecular Inversion Probes and Next-Generation Sequencing

March 30, 2020 - 10:49 -- NOT Open Access
Mensah BA, Aydemir O, Myers-Hansen JL, Opoku M, Hathaway NJ, Marsh PW, Anto F, Bailey J, Abuaku B, Ghansah A
Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e01423-19

A key drawback to monitoring the emergence and spread of antimalarial drug resistance in sub-Saharan Africa is early detection and containment. Next-generation sequencing methods offer the resolution, sensitivity, and scale required to fill this gap by surveilling for molecular markers of drug resistance.

Molecular detection of antimalarial drug resistance in Plasmodium vivax from returned travellers to NSW, Australia during 2008-2018

February 16, 2020 - 09:23 -- Open Access
Noisang C, Meyer W, Sawangjaroen N, Ellis J, Lee R
Pathogens. 2020 Feb 5;9(2). pii: E101

To monitor drug resistance in Plasmodium vivax, a multidrug resistance 1 (Pvmdr1) gene and a putative transporter protein (Pvcrt-o) gene were used as molecular markers for chloroquine resistance. The biomarkers, the dihydrofolate reductase (Pvdhfr) gene and the dihydropteroate synthetase (Pvdhps) gene, were also used for the detection of resistance to sulphadoxine-pyrimethamine (SP); this drug is often accidentally used to treat P. vivax infections. Clinical blood samples (n = 120) were collected from patients who had been to one of eight malaria-endemic countries and diagnosed with P. vivax infection.

Capacity Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance Monitoring in Africa Network

November 5, 2017 - 18:34 -- Open Access
Eric S. Halsey, Meera Venkatesan, Venkatachalam Udhayakumar, et al.
Emerging Infectious Diseaes , Volume 23, Supplement—December 2017

Antimalarial drug resistance is an evolving global health security threat to malaria control.

Early detection of Plasmodium falciparum resistance through therapeutic efficacy studies and associated genetic analyses may facilitate timely implementation of intervention strategies. The US President’s Malaria Initiative–supported Antimalarial Resistance Monitoring in Africa (PARMA) Network has assisted numerous laboratories in partner countries in acquiring the knowledge and capability to independently monitor for molecular markers of antimalarial drug resistance.

Subscribe to RSS - antimalarial drug resistance